CJC-1295 belongs to a category of peptides called growth hormone secretagogues — compounds that signal the pituitary gland to produce and release more growth hormone. It's one of the more rigorously studied peptides on the expected reclassification list, with actual human clinical trial data behind it.
That's worth noting, because it sets CJC-1295 apart from many of the other compounds in this cluster.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — the naturally occurring hormone that tells your pituitary gland to release growth hormone. The key engineering behind CJC-1295 is its extended half-life. Natural GHRH degrades quickly in the body. CJC-1295 is modified to bind to albumin in the bloodstream, which protects it from enzymatic breakdown and dramatically extends its activity — with a half-life estimated at around six to eight days.
It comes in two forms: with DAC (Drug Affinity Complex), which further extends the half-life, and without DAC (sometimes called Modified GRF 1-29), which acts more quickly. The version with DAC is more commonly prescribed in clinical contexts.
What the human research actually shows
This is where CJC-1295 stands out. A 2006 randomized, placebo-controlled, double-blind trial published in the Journal of Clinical Endocrinology & Metabolism found that a single subcutaneous injection of CJC-1295 produced dose-dependent increases in mean plasma growth hormone concentrations of two to ten times for six or more days, and increases in IGF-1 concentrations of 1.5 to three times for nine to eleven days in healthy adults ages 21 to 61.
A follow-up study found that CJC-1295 increased growth hormone secretion while preserving the natural pulsatile pattern — meaning it augments rather than replaces the body's normal GH rhythm. No serious adverse reactions were reported in these trials.
Areas of clinical interest based on the research include support for age-related growth hormone decline, sleep quality, metabolic support, and potential applications in muscle wasting conditions.
The honest version: human studies confirm CJC-1295 reliably raises GH and IGF-1 levels. What the research doesn't yet clearly establish is whether those hormonal changes translate predictably into specific outcomes like fat loss, muscle gain, or injury recovery in healthy adults. More research is needed to connect mechanism to clinical outcome.
CJC-1295 is currently not legally available through licensed compounding pharmacies in the United States. The Category 2 restriction placed in 2023 remains in effect until the FDA formally publishes its updated compounding list. The February 2026 announcement signals that CJC-1295 is expected to return to legal compounding status, but that process isn't complete.
When it does become available, the clinical data behind CJC-1295 — including the human trials — puts it in a relatively strong position among the peptides expected to return. Working with a licensed provider at that point will be important for appropriate dosing and monitoring.
In the meantime, Belle's currently available programs include compounded GLP-1 therapy, NAD+, and MIC+B12.
Explore Belle's currently available programs.
Belle offers provider-guided compounded medication programs. Peptide compounds are not FDA-approved drugs. Access requires a licensed provider's prescription. Always work with a qualified medical professional before beginning any new therapy.
